Inspire Medical Systems to Report Q1 2026 Earnings on May 4

The medical device company will host a conference call to discuss financial results and business updates.

Apr. 6, 2026 at 1:41pm

Got story updates? Submit your updates here. ›

Inspire Medical Systems, Inc., a medical technology company focused on innovative solutions for obstructive sleep apnea, will release its financial results for the first quarter of 2026 after the market close on Monday, May 4. The company will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results and provide updates on its business.

Why it matters

Inspire's Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea, making the company's quarterly financial performance and product updates important for investors and the sleep apnea treatment market.

The details

Inspire will release its Q1 2026 financial results after the market close on May 4, 2026. The company will then host a conference call at 5:00 p.m. Eastern Time the same day to discuss the results. Investors can access the webcast of the call through Inspire's Investor Relations website or by registering for the call to receive dial-in details. A replay of the call will be available on Inspire's website following the event.

  • Inspire will release Q1 2026 financial results after the market close on May 4, 2026.
  • Inspire will host a conference call to discuss the results at 5:00 p.m. Eastern Time on May 4, 2026.

The players

Inspire Medical Systems, Inc.

A medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea.

Ezgi Yagci

Vice President of Investor Relations at Inspire Medical Systems.

Got photos? Submit your photos here. ›

What they’re saying

“A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q1 2026 earnings call webcast.”

— Inspire Medical Systems

“If you plan to ask a question, please use the following link: Inspire's Q1 2026 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call.”

— Inspire Medical Systems

What’s next

Investors can access the webcast of Inspire's Q1 2026 earnings call through the company's Investor Relations website or by registering for the call to receive dial-in details. A replay of the call will be available on Inspire's website following the event.

The takeaway

Inspire Medical Systems' quarterly financial performance and updates on its Inspire therapy, the first FDA-approved neurostimulation treatment for obstructive sleep apnea, are important for investors and the sleep apnea treatment market. The company's upcoming Q1 2026 earnings call will provide insight into the continued development and commercialization of this innovative medical technology.